Clinical Analysis of Trastuzumab-Targeted and Chemotherapy Treatment for Breast Cancer Patients

© 2024 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

HTML

Abstract

Objective: To explore the clinical effectiveness and safety of trastuzumab combined with chemotherapy in breast cancer patients. Methods: Eighty patients with postoperative local recurrence of breast cancer were divided into a control group (chemotherapy only) and an observation group (chemotherapy plus trastuzumab-targeted therapy). The clinical efficacy, adverse reactions, and complications were compared between groups. Results: The overall effective rate of clinical treatment in the observation group was higher than that in the control group (P < 0.05). The incidence of adverse reactions showed no difference between the groups (P > 0.05), while the complication rate was significantly lower in the observation group (P < 0.05). Conclusion: Trastuzumab-targeted therapy combined with chemotherapy can significantly improve clinical treatment outcomes for breast cancer patients, reduce the risk of complications, and maintain good safety, making it suitable for clinical promotion.

References

Hu YR, Shang YN, Ma PS, et al., 2022, Effects of Magnetic Resonance Evaluation on Cardiac Structure and Function in Breast Cancer Patients Undergoing Chemotherapy Combined with Targeted Therapy. J Chin Med Imaging, 30(6): 541–547.

Zhang XY, Zhang H, Yang YY, et al., 2019, Effects of Trastuzumab Combined with Paclitaxel and Carboplatin Neoadjuvant Chemotherapy on HER2-Positive Breast Cancer and Its Impact on Cardiac Function and Short-Term Prognosis. Clin Misdiagnosis Mistherapy, 32(10): 51–56.

Wang P, Chen LJ, Qian CX, 2022, Effects of Chemotherapy Combined with Trastuzumab on HER2-Positive Metastatic Breast Cancer and Serum Tumor Markers. J Math Med, 35(10): 1521–1523.

Shi EJ, Wu QR, 2021, Clinical Efficacy and Safety of Chemotherapy Combined with Trastuzumab in HER2-Positive Metastatic Breast Cancer. Med Equip, 34(7): 91–92.

Li Y, Liu X, Zeng WR, et al., 2019, Efficacy of Trastuzumab Combined with Neoadjuvant Chemotherapy on HER2-Positive Breast Cancer. Clin Med Res Pract, 4(35): 85–87.

Liu SJ, Chen XL, Su WY, et al., 2022, Clinical Observation of Skin Adverse Reactions in Breast Cancer Patients Treated with Trastuzumab and Pertuzumab. J Inner Mongolia Med Univ, 44(2): 161–164.

Cheng YJ, Xu L, Ye JM, et al., 2020, Efficacy of Pertuzumab and Trastuzumab Combined with Chemotherapy in Neoadjuvant Treatment of Early Breast Cancer. Chin J Clin Med (Electronic Edition), 14(5): 344–348.

Tong EJ, Shang BB, Wang MM, et al., 2022, Clinical Efficacy of Targeted Drug Herceptin Combined with Chemotherapy in Advanced Breast Cancer and Its Effect on Patient Inflammatory Factors. Chin Pract Med, 17(23): 148–150.

Huang HQ, Wang YX, Lin WQ, et al., 2022, Study on the Short-Term Efficacy and Quality of Life Effects of Trastuzumab-Targeted Therapy in Breast Cancer Patients After Modified Radical Mastectomy. Pharm Biotechnol, 29(6): 594–597.

Previous article in this issue

Next article in this issue